9 November 2021|
Skadden advised Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited and Credit Suisse (Hong Kong) Limited as lead underwriters on Clover Biopharmaceuticals, Ltd.'s initial public offering and listing on the Main Board of the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules. Clover Biopharmaceuticals offered 150,000,000 shares at HK$13.38 per share, for an approximate total offer value of HK$2 billion (approximately US$257.8 million), exclusive of over-allotment options. Trading commenced on November 5.
Clover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
The Skadden team was led by partners Julie Gao (Hong Kong) and Paloma Wang (Hong Kong), with counsel Kai Sun (Hong Kong), associates Ming Kong (Hong Kong), Nicole Yuen (Hong Kong), Tina Ye (Hong Kong), Xinjia Wang (Hong Kong), and international legal project manager Ryann An (Beijing), staff attorney Diana Wan (Hong Kong), and trainee solicitor Nicholas Poon (Hong Kong).
For further information, please contact:
Grace Lord, Marketing & Communications Specialist, Skadden
grace.lord@skadden.com
